Autolus Therapeutics plc

Autolus Therapeutics plc Earnings Recaps

AUTL Health Care 3 recaps
Q1 2026 May 18, 2026

Shares fell 4.7% after earnings despite an unchanged full-year revenue outlook, reflecting investor concern about slowing growth momentum and cautious incremental progress during the commercial launch phase.

Key takeaways
  • Q1 revenue of $26.2 million, with unchanged 2026 full-year guidance of $120 million to $135 million.
  • First quarter showing positive gross margin, attributed to operational efficiencies and increased volume at the manufacturing plant.
  • Early U.S. and U.K. commercial launches progressing with 73 U.S. centers active, expected to exceed 80 by year-end; over 10 centers active in the U.K. under NHS access.
  • Product optimization efforts include a 13% workforce reduction aimed at improving cost structure, targeting a peak gross margin of 65-70% for the core ALL business.
  • Pipeline progress continues with pediatric Phase II expansion underway and data expected near end of 2027; FDA alignment on protocol for registration.
Full recap
Q3 2025 Nov 12, 2025

Autolus Therapeutics reported a strong launch of Obe-cel in Q3 2025, achieving $21.1 million in net sales, with significant market access and operational stability enhancing growth prospects.

Key takeaways
  • Q3 2025 net sales for Obe-cel reached $21.1 million, bringing total sales for the first nine months to $51 million.
  • The company successfully authorized 60 treatment centers in the U.S., exceeding its initial target for the year.
  • Patient access achieved for over 90% of U.S. covered lives, supporting high manufacturing success rates above 90%.
  • Growth potential in the CAR T market appears robust, with current market share in active centers estimated at 20%.
  • New leadership appointments bolster operational efficiency and strategic direction moving forward.
Full recap
Q2 2025 Aug 12, 2025

Autolus Therapeutics reported a strong second quarter with $20.9 million in product sales for Obe-cel, demonstrating solid momentum in its commercial launch and expanding market access potential.

Key takeaways
  • Generated $20.9 million in product sales in Q2, bringing YTD total to $29.9 million.
  • Expanded to 46 authorized treatment centers in the U.S. with 90% medical lives covered.
  • Achieved permanent HCPCS code effective July 1, 2025, aiding reimbursement processes despite initial patient enrollment slowdowns.
  • Expecting the Phase I results of OviCel's pediatric study by year-end, with plans to broaden its application.
  • R&D expenses decreased to $27.4 million, reflecting strategic shifts as commercial manufacturing scales up.
Full recap